| 40 |
Durazzo TC, Mattsson N, Weiner MW, et al. Smoking and increased Alzheimer's disease risk: a review of potential mechanisms [J]. Alzheimers Dement, 2014, 10(3 Suppl): S122-S145.
|
| 41 |
Norton MC, Dew J, Smith H, et al. Lifestyle behavior pattern is associated with different levels of risk for incident dementia and Alzheimer's disease: the Cache County study [J]. J Am Geriatr Soc, 2012, 60(3): 405-412.
|
| 42 |
Seixas AA, Turner AD, Bubu OM, et al. Obesity and race may explain differential burden of white matter hyperintensity load [J]. Clin Interv Aging, 2021, 16: 1563-1571.
|
| 43 |
Ishii M, Iadecola C. Adipocyte-derived factors in age-related dementia and their contribution to vascular and Alzheimer pathology [J]. Biochim Biophys Acta, 2016, 1862(5): 966-974.
|
| 44 |
Anjum I, Fayyaz M, Wajid A, et al. Does obesity increase the risk of dementia: a literature review [J]. Cureus, 2018, 10(5): e2660.
|
| 45 |
Nebel RA, Aggarwal NT, Barnes LL, et al. Understanding the impact of sex and gender in Alzheimer's disease: a call to action [J]. Alzheimers Dement, 2018, 14(9): 1171-1183.
|
| 46 |
Podcasy JL, Epperson CN. Considering sex and gender in Alzheimer disease and other dementias [J]. Dialogues Clin Neurosci, 2016, 18(4): 437-446.
|
| 47 |
Sedaghat S, Lutsey PL, Ji Y, et al. Association of change in cardiovascular risk factors with incident dementia [J]. Alzheimers Dement, 2023, 19(5): 1821-1831.
|
| 48 |
Torres S, Alexander A, O'bryant S, et al. Cognition and the predictive utility of three risk scores in an ethnically diverse sample [J]. J Alzheimers Dis, 2020, 75(3): 1049-1059.
|
| 49 |
Song R, Xu H, Dintica CS, et al. Associations between cardiovascular risk, structural brain changes, and cognitive decline [J]. J Am Coll Cardiol, 2020, 75(20): 2525-2534.
|
| 50 |
Wang R, Fratiglioni L, Kalpouzos G, et al. Mixed brain lesions mediate the association between cardiovascular risk burden and cognitive decline in old age: a population-based study [J]. Alzheimers Dement, 2017, 13(3): 247-256.
|
| 51 |
Jin Y, Liang J, Hong C, et al. Cardiometabolic multimorbidity, lifestyle behaviours, and cognitive function: a multicohort study [J]. Lancet Healthy Longev, 2023, 4(6): e265-e273.
|
| 52 |
Yaffe K, Vittinghoff E, Hoang T, et al. Cardiovascular risk factors across the life course and cognitive decline: a pooled cohort study [J]. Neurology, 2021, 96(17): e2212-e2219.
|
| 53 |
Scheffer S, Hermkens DMA, Weerd LVD, et al. Vascular hypothesis of Alzheimer disease [J]. Arterioscler Thromb Vasc Biol, 2021, 41(4): 1265-1283.
|
| 54 |
Zlokovic BV, Gottesman RF, Bernstein KE, et al. Vascular contributions to cognitive impairment and dementia (VCID): a report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop [J]. Alzheimers Dement, 2020, 16(12): 1714-1733.
|
| 55 |
Sweeney MD, Montagne A, Sagare AP, et al. Vascular dysfunction-The disregarded partner of Alzheimer's disease [J]. Alzheimers Dement, 2019, 15(1): 158-167.
|
| 56 |
Mcaleese KE, Colloby SJ, Thomas AJ, et al. Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia [J]. Alzheimers Dement, 2021, 17(7): 1121-1133.
|
| 57 |
Markus HS, De Leeuw FE. Cerebral small vessel disease: Recent advances and future directions [J]. Int J Stroke, 2023, 18(1): 4-14.
|
| 58 |
Kim WSH, Luciw NJ, Atwi S, et al. Associations of white matter hyperintensities with networks of gray matter blood flow and volume in midlife adults: a coronary artery risk development in young adults magnetic resonance imaging substudy [J]. Hum Brain Mapp, 2022, 43(12): 3680-3693.
|
| 59 |
Jiang X, Lewis CE, Allen NB, et al. Premature cardiovascular disease and brain health in midlife: the CARDIA study [J]. Neurology, 2023, 100(14): e1454-e1463.
|
| 60 |
Affleck AJ, Sachdev PS, Halliday GM. Past antihypertensive medication use is associated with lower levels of small vessel disease and lower Aβ plaque stage in the brains of older individuals [J]. Neuropathol Appl Neurobiol, 2023, 49(4): e12922.
|
| 61 |
Karami N, Kazeminia M, Karami A, et al. Global prevalence of depression, anxiety, and stress in cardiac patients: a systematic review and meta-analysis [J]. J Affect Disord, 2023, 324: 175-189.
|
| 62 |
Warriach ZI, Patel S, Khan F, et al. Association of depression with cardiovascular diseases [J]. Cureus, 2022, 14(6): e26296.
|
| 63 |
Goldfarb M, De Hert M, Detraux J, et al. Severe mental illness and cardiovascular disease: JACC state-of-the-art review [J]. J Am Coll Cardiol, 2022, 80(9): 918-933.
|
| 64 |
Arnaud AM, Brister TS, Duckworth K, et al. Impact of major depressive disorder on comorbidities: a systematic literature review [J]. J Clin Psychiatry, 2022, 83(6): 21r14328.
|
| 65 |
Jack Jr CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease [J]. Alzheimers Dement, 2018, 14(4): 535-562.
|
| 66 |
Salvadó G, Milà-Alomà M, Shekari M, et al. Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer's continuum [J]. Eur J Nucl Med Mol Imaging, 2022, 49(13): 4567-4579.
|
| 67 |
Chételat G, Arbizu J, Barthel H, et al. Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias [J]. Lancet Neurol, 2020, 19(11): 951-962.
|
| 68 |
Cortes-Canteli M, Gispert JD, Salvadó G, et al. Subclinical atherosclerosis and brain metabolism in middle-aged individuals: the PESA study [J]. J Am Coll Cardiol, 2021, 77(7): 888-898.
|
| 69 |
Zetterberg H, Blennow K. Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics [J]. Mol Neurodegener, 2021, 16(1): 10.
|
| 70 |
Hachinski V, Einhäupl K, Ganten D, et al. Preventing dementia by preventing stroke: the Berlin Manifesto [J]. Alzheimers Dement, 2019, 15(7): 961-984.
|
| 71 |
Grande G, Ljungman PLS, Eneroth K, et al. Association between cardiovascular disease and long-term exposure to air pollution with the risk of dementia [J]. JAMA Neurology, 2020, 77(7): 801-809.
|
| 72 |
Cortes-Canteli M, Iadecola C. Alzheimer's disease and vascular aging: JACC focus seminar [J]. J Am Coll Cardiol, 2020, 75(8): 942-951.
|
| 73 |
De Anda-Duran I, Alonso CF, Libon DJ, et al. Carotid intima-media thickness and midlife cognitive function: impact of race and social disparities in the Bogalusa heart study [J]. Neurology, 2022, 98(18): e1828-e1836.
|
| 74 |
Cermakova P, Ding J, Meirelles O, et al. Carotid intima–media thickness and markers of brain health in a biracial middle-aged cohort: CARDIA brain MRI sub-study [J]. J Gerontol A Biol Sci Med Sci, 2020, 75(2): 380-386.
|
| 75 |
Wang W, Norby FL, Alonso A, et al. Association of carotid intima-media thickness with brain MRI markers in the atherosclerosis risk in communities neurocognitive study (ARIC-NCS) [J]. J Stroke Cerebrovasc Dis, 2022, 31(5): 106388.
|
| 76 |
Azahar NM, Yano Y, Kadota A, et al. Association of arterial stiffness and atherosclerotic burden with brain structural changes among Japanese men [J]. J Am Heart Assoc, 2023, 12(11): e028586.
|
| 77 |
Kang KM, Byun MS, Lee JH, et al. Association of carotid and intracranial stenosis with Alzheimer's disease biomarkers [J]. Alzheimers Res Ther, 2020, 12(1): 106.
|
| 1 |
2023 Alzheimer's disease facts and figures [J]. Alzheimers Dement, 2023, 19(4): 1598-695.
|
| 2 |
Cummings J, Lee G, Ritter A, et al. Alzheimer's disease drug development pipeline: 2018 [J]. Alzheimers Dement (N Y), 2018, 4: 195-214.
|
| 3 |
Collaborators GBDD. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 [J]. Lancet Neurol, 2019, 18(1): 88-106.
|
| 4 |
Santos CY, Snyder PJ, Wu WC, et al. Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: a review and synthesis [J]. Alzheimers Dement (Amst), 2017, 7(1): 69-87.
|
| 5 |
Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission [J]. Lancet, 2020, 396(10248): 413-446.
|
| 6 |
Mehta RI, Schneider JA. What is 'Alzheimer's disease'? The neuropathological heterogeneity of clinically defined Alzheimer's dementia [J]. Curr Opin Neurol, 2021, 34(2): 237-245.
|
| 7 |
Emrani S, Lamar M, Price CC, et al. Alzheimer's/vascular spectrum dementia: classification in addition to diagnosis [J]. J Alzheimers Dis, 2020, 73(1): 63-71.
|
| 8 |
Qiu C. Preventing Alzheimer's disease by targeting vascular risk factors: hope and gap [J]. J Alzheimers Dis, 2012, 32(3): 721-731.
|
| 9 |
Attems J, Jellinger KA. The overlap between vascular disease and Alzheimer's diseaselessons from pathology [J]. BMC Med, 2014, 12(1): 206.
|
| 10 |
Dubois B, Hampel H, Feldman HH, et al. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria [J]. Alzheimers Dement, 2016, 12(3): 292-323.
|
| 11 |
Collaborators GBDDF. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019 [J]. Lancet Public Health, 2022, 7(2): e105-e125.
|
| 12 |
Chan KY, Wang W, Wu JJ, et al. Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990-2010: a systematic review and analysis [J]. Lancet, 2013, 381(9882): 2016-2023.
|
| 13 |
Gao S, Ogunniyi A, Hall KS, et al. Dementia incidence declined in African-Americans but not in Yoruba [J]. Alzheimers Dement, 2016, 12(3): 244-251.
|
| 14 |
Ohara T, Hata J, Yoshida D, et al. Trends in dementia prevalence, incidence, and survival rate in a Japanese community [J]. Neurology, 2017, 88(20): 1925-1932.
|
| 15 |
Wu YT, Beiser AS, Breteler MMB, et al. The changing prevalence and incidence of dementia over time-current evidence [J]. Nat Rev Neurol, 2017, 13(6): 327-339.
|
| 16 |
Satizabal CL, Beiser AS, Chouraki V, et al. Incidence of dementia over three decades in the Framingham heart study [J]. N Engl J Med, 2016, 374(6): 523-532.
|
| 17 |
Ding M, Qiu C, Rizzuto D, et al. Tracing temporal trends in dementia incidence over 25 years in central Stockholm, Sweden [J]. Alzheimers Dement, 2020, 16(5): 770-778.
|
| 18 |
Kivipelto M, Mangialasche F, Snyder HM, et al. World-Wide FINGERS Network: a global approach to risk reduction and prevention of dementia [J]. Alzheimers Dement, 2020, 16(7): 1078-1094.
|
| 19 |
Boyle PA, Yu L, Wilson RS, et al. Person-specific contribution of neuropathologies to cognitive loss in old age [J]. Ann Neurol, 2018, 83(1): 74-83.
|
| 20 |
Ou YN, Tan CC, Shen XN, et al. Blood pressure and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 209 prospective studies [J]. Hypertension, 2020, 76(1): 217-225.
|
| 21 |
Albanese E, Launer LJ, Egger M, et al. Body mass index in midlife and dementia: systematic review and meta-regression analysis of 589,649 men and women followed in longitudinal studies [J]. Alzheimers Dement (Amst), 2017, 8: 165-178.
|
| 22 |
Chatterjee S, Peters SA, Woodward M, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia [J]. Diabetes Care, 2016, 39(2): 300-307.
|
| 23 |
Iadecola C. Hypertension and dementia [J]. Hypertension, 2014, 64(1): 3-5.
|
| 24 |
Ingaramo RA. Obesity, diabetes, and other cardiovascular risk factors in native populations of South America [J]. Curr Hypertens Rep, 2016, 18(1): 9.
|
| 25 |
Noale M, Limongi F, Maggi S. Epidemiology of cardiovascular diseases in the elderly [J]. Adv Exp Med Biol, 2020, 1216: 29-38.
|
| 26 |
Den Brok M, Van Dalen JW, Marcum ZA, et al. Year-by-year blood pressure variability from midlife to death and lifetime dementia risk [J]. JAMA Netw Open, 2023, 6(10): e2340249.
|
| 27 |
Thorin E. Hypertension and Alzheimer disease: another brick in the wall of awareness [J]. Hypertension, 2015, 65(1): 36-38.
|
| 28 |
Chen Y, Araghi M, Bandosz P, et al. Impact of hypertension prevalence trend on mortality and burdens of dementia and disability in England and Wales to 2060: a simulation modelling study [J]. Lancet Healthy Longev, 2023, 4(9): e470-e477.
|
| 29 |
Sergi D, Zauli E, Tisato V, et al. Lipids at the Nexus between cerebrovascular disease and vascular dementia: the impact of HDL-cholesterol and ceramides [J]. Int J Mol Sci, 2023, 24(5): 4403.
|
| 30 |
Wee J, Sukudom S, Bhat S, et al. The relationship between midlife dyslipidemia and lifetime incidence of dementia: a systematic review and meta-analysis of cohort studies [J]. Alzheimers Dement (Amst), 2023, 15(1): e12395.
|
| 31 |
Power MC, Rawlings A, Sharrett AR, et al. Association of midlife lipids with 20-year cognitive change: a cohort study [J]. Alzheimers Dement, 2018, 14(2): 167-177.
|
| 32 |
Troncone L, Luciani M, Coggins M, et al. Abeta amyloid pathology affects the hearts of patients with Alzheimer's disease: mind the heart [J]. J Am Coll Cardiol, 2016, 68(22): 2395-2407.
|
| 33 |
Xiang J. Carotid atherosclerosis promotes the progression of Alzheimer's disease: a three-year prospective study [J]. Exp Ther Med, 2017, 14(2): 1321-1326.
|
| 34 |
Sjogren M, Mielke M, Gustafson D, et al. Cholesterol and Alzheimer's disease--is there a relation? [J]. Mech Ageing Dev, 2006, 127(2): 138-147.
|
| 35 |
Hamal C, Velugoti L, Tabowei G, et al. Metformin for the improvement of comorbid depression symptoms in diabetic patients: a systematic review [J]. Cureus, 2022, 14(8): e28609.
|
| 36 |
Kim WJ, Noh JH, Han K, et al. The association between second-line oral antihyperglycemic medication on types of dementia in type 2 diabetes: a nationwide real-world longitudinal study [J]. J Alzheimers Dis, 2021, 81(3): 1263-1272.
|
| 37 |
Norgaard CH, Friedrich S, Hansen CT, et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers [J]. Alzheimers Dement (N Y), 2022, 8(1): e12268.
|
| 38 |
Wu CY, Iskander C, Wang C, et al. Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study [J]. Diabetes Care, 2023, 46(2): 297-304.
|
| 78 |
Gottesman RF, Mosley TH, Knopman DS, et al. Association of intracranial atherosclerotic disease with brain β-amyloid deposition: secondary analysis of the ARIC study [J]. JAMA Neurol, 2020, 77(3): 350-357.
|
| 79 |
Gottesman RF, Schneider ALC, Zhou Y, et al. Association between midlife vascular risk factors and estimated brain amyloid deposition [J]. JAMA, 2017, 317(14): 1443-1450.
|
| 80 |
Group SOW, Collaboration ECR. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions [J]. Eur Heart J, 2021, 42(25): 2455-2467.
|
| 81 |
Rodondi N, Locatelli I, Aujesky D, et al. Framingham risk score and alternatives for prediction of coronary heart disease in older adults [J]. PLoS One, 2012, 7(3): e34287.
|
| 82 |
Dalton JE, Rothberg MB, Dawson NV, et al. Failure of traditional risk factors to adequately predict cardiovascular events in older populations [J]. J Am Geriatr Soc, 2020, 68(4): 754-761.
|
| 83 |
Nanna MG, Peterson ED, Wojdyla D, et al. The accuracy of cardiovascular pooled cohort risk estimates in U.S. older adults [J]. J Gen Intern Med, 2020, 35(6): 1701-1708.
|
| 84 |
Van Trier TJ, Snaterse M, Boekholdt SM, et al. Validation of systematic coronary risk evaluation 2 (SCORE2) and SCORE2-older persons in the EPIC-norfolk prospective population cohort [J]. Eur J Prev Cardiol, 2023: zwad318. Online ahead of print.
|
| 85 |
Sabia S, Fayosse A, Dumurgier J, et al. Association of ideal cardiovascular health at age 50 with incidence of dementia: 25 year follow-up of Whitehall II cohort study [J]. BMJ, 2019, 366: l4414.
|
| 86 |
Tristão-Pereira C, Fuster V, Oliva B, et al. Longitudinal interplay between subclinical atherosclerosis, cardiovascular risk factors, and cerebral glucose metabolism in midlife: results from the PESA prospective cohort study [J]. Lancet Healthy Longev, 2023, 4(9): e487-e498.
|
| 87 |
Andrieu S, Coley N, Lovestone S, et al. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions [J]. Lancet Neurol, 2015, 14(9): 926-944.
|
| 88 |
Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial [J]. Lancet, 2015, 385(9984): 2255-2263.
|
| 89 |
Andrieu S, Guyonnet S, Coley N, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial [J]. Lancet Neurol, 2017, 16(5): 377-389.
|
| 90 |
Moll Van Charante EP, Richard E, Eurelings LS, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial [J]. Lancet, 2016, 388(10046): 797-805.
|
| 91 |
Solomon A, Stephen R, Altomare D, et al. Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services-part 4 of 6 [J]. Alzheimers Res Ther, 2021, 13(1): 171.
|
| 39 |
Tang H, Shao H, Shaaban CE, et al. Newer glucose-lowering drugs and risk of dementia: a systematic review and meta-analysis of observational studies [J]. J Am Geriatr Soc, 2023, 71(7): 2096-2106.
|